{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:06:46Z","timestamp":1790662006700,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 R01 HL126903-02"],"award-info":[{"award-number":["5 R01 HL126903-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VA Merit Review","award":["5I01CX000829\u201104"],"award-info":[{"award-number":["5I01CX000829\u201104"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Blood pressure (BP) in the office is often recorded without standardization of the technique of measurement. When office BP measurement is performed with a research-grade methodology, it can inform better therapeutic decisions. The reference-standard method of ambulatory BP monitoring (ABPM) together with the assessment of BP in the office enables the identification of white-coat and masked hypertension, facilitating the stratification of cardiorenal risk. Compared with general population, the prevalence of resistant hypertension is 2- to 3-fold higher among patients with chronic kidney disease (CKD). The use of ABPM is mandatory in order to exclude the white-coat effect, a common cause of pseudoresistance, and confirm the diagnosis of true-resistant hypertension. After the premature termination of Systolic Blood Pressure Intervention Trial due to an impressive cardioprotective benefit of intensive BP-lowering, the 2017 American Heart Association\/American College of Cardiology guideline reappraised the definition of hypertension and recommended a tighter BP target of &amp;lt;130\/80 mm Hg for the majority of adults with a high cardiovascular risk profile, inclusive of patients with CKD. However, the benefit\/risk ratio of intensive BP-lowering in particular subsets of patients with CKD (i.e., those with diabetes or more advanced CKD) continues to be debated. We explore the controversial issue of BP targets in CKD, providing a critical evaluation of the available clinical-trial evidence and guideline recommendations. We argue that the systolic BP target in CKD, if BP is measured correctly, should be &amp;lt;120 mm Hg.<\/jats:p>","DOI":"10.1093\/ajh\/hpaa209","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T20:21:23Z","timestamp":1607977283000},"page":"318-326","source":"Crossref","is-referenced-by-count":25,"title":["Hypertension in Chronic Kidney Disease (CKD): Diagnosis, Classification, and Therapeutic Targets"],"prefix":"10.1093","volume":"34","author":[{"given":"Panagiotis I","family":"Georgianos","sequence":"first","affiliation":[{"name":"Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"2021042014202486100_CIT0001","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2021042014202486100_CIT0002","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"2021042014202486100_CIT0003","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2021042014202486100_CIT0004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/HYPERTENSIONAHA.116.08076","article-title":"Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory blood pressure study","volume":"69","author":"Drawz","year":"2017","journal-title":"Hypertension"},{"key":"2021042014202486100_CIT0005","doi-asserted-by":"crossref","first-page":"e004536","DOI":"10.1161\/JAHA.116.004536","article-title":"Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"6","author":"Agarwal","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2021042014202486100_CIT0006","doi-asserted-by":"crossref","first-page":"JC69","DOI":"10.7326\/ACPJ201906180-069","article-title":"Review: automated office BP measures are similar to awake ambulatory BP and lower than other office BP measures","volume":"170","author":"Georgianos","year":"2019","journal-title":"Ann Intern Med"},{"key":"2021042014202486100_CIT0007","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/HJH.0000000000000221","article-title":"European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring","volume":"32","author":"Parati","year":"2014","journal-title":"J Hypertens"},{"key":"2021042014202486100_CIT0008","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2215\/CJN.13181117","article-title":"Variations in 24-hour BP profiles in cohorts of patients with kidney disease around the world: the I-DARE study","volume":"13","author":"Drawz","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021042014202486100_CIT0009","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.05391008","article-title":"Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis","volume":"4","author":"Bangash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021042014202486100_CIT0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1681\/ASN.2015030243","article-title":"Masked uncontrolled hypertension in CKD","volume":"27","author":"Agarwal","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2021042014202486100_CIT0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MNH.0b013e3283336ddb","article-title":"Regulation of circadian blood pressure: from mice to astronauts","volume":"19","author":"Agarwal","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2021042014202486100_CIT0012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/01.HYP.0000178102.85718.66","article-title":"Correlates of systolic hypertension in patients with chronic kidney disease","volume":"46","author":"Agarwal","year":"2005","journal-title":"Hypertension"},{"key":"2021042014202486100_CIT0013","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1093\/ndt\/gfp074","article-title":"GFR, proteinuria and circadian blood pressure","volume":"24","author":"Agarwal","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2021042014202486100_CIT0014","first-page":"2058","article-title":"Albuminuria and masked uncontrolled hypertension in chronic kidney disease","volume":"32","author":"Agarwal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2021042014202486100_CIT0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000097366","article-title":"Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease","volume":"26","author":"Agarwal","year":"2006","journal-title":"Am J Nephrol"},{"key":"2021042014202486100_CIT0016","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.ki.5000081","article-title":"Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease","volume":"69","author":"Agarwal","year":"2006","journal-title":"Kidney Int"},{"key":"2021042014202486100_CIT0017","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archinternmed.2011.230","article-title":"Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease","volume":"171","author":"Minutolo","year":"2011","journal-title":"Arch Intern Med"},{"key":"2021042014202486100_CIT0018","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.ajkd.2014.06.014","article-title":"Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study","volume":"64","author":"Minutolo","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2021042014202486100_CIT0019","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2021042014202486100_CIT0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11906-020-01081-x","article-title":"Resistant hypertension in chronic kidney disease (CKD): prevalence, treatment particularities, and research agenda","volume":"22","author":"Georgianos","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"2021042014202486100_CIT0021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"2021042014202486100_CIT0022","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021042014202486100_CIT0023","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.ajkd.2013.11.016","article-title":"Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study","volume":"63","author":"Tanner","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2021042014202486100_CIT0024","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jacc.2012.12.061","article-title":"Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients","volume":"61","author":"De Nicola","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2021042014202486100_CIT0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1751-7176.2011.00556.x","article-title":"Refractory hypertension: definition, prevalence, and patient characteristics","volume":"14","author":"Acelajado","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2021042014202486100_CIT0026","doi-asserted-by":"crossref","first-page":"e007365","DOI":"10.1161\/JAHA.117.007365","article-title":"Prevalence and clinical characteristics of refractory hypertension","volume":"6","author":"Armario","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2021042014202486100_CIT0027","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HJH.0000000000002103","article-title":"Prevalence of refractory hypertension in the United States from 1999 to 2014","volume":"37","author":"Buhnerkempe","year":"2019","journal-title":"J Hypertens"},{"key":"2021042014202486100_CIT0028","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.07440618","article-title":"Blood pressure goals in patients with CKD: a review of evidence and guidelines","volume":"14","author":"Chang","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021042014202486100_CIT0029","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11886-015-0650-4","article-title":"What are optimal blood pressure targets for patients with hypertension and chronic kidney disease?","volume":"17","author":"Modi","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"2021042014202486100_CIT0030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/jch.13859","article-title":"Blood pressure targets in patients with chronic kidney disease: a critical evaluation of clinical-trial evidence and guideline recommendations","volume":"22","author":"Georgianos","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2021042014202486100_CIT0031","first-page":"337","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group: KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","author":"Becker","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021042014202486100_CIT0032","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2021042014202486100_CIT0033","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"2021042014202486100_CIT0034","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"2021042014202486100_CIT0035","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2021042014202486100_CIT0036","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"2021042014202486100_CIT0037","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021042014202486100_CIT0038","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"2021042014202486100_CIT0039","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-154-8-201104190-00335","article-title":"Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier","volume":"154","author":"Upadhyay","year":"2011","journal-title":"Ann Intern Med"},{"key":"2021042014202486100_CIT0040","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N Engl J Med"},{"key":"2021042014202486100_CIT0041","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","article-title":"The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann Intern Med"},{"key":"2021042014202486100_CIT0042","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/HYPERTENSIONAHA.113.01501","article-title":"Are observational studies more informative than randomized controlled trials in hypertension? Con side of the argument","volume":"62","author":"Schillaci","year":"2013","journal-title":"Hypertension"},{"key":"2021042014202486100_CIT0043","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine\u2013reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"},{"key":"2021042014202486100_CIT0044","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.118.10850","article-title":"Office blood pressure measurement: the weak cornerstone of hypertension diagnosis","volume":"71","author":"Stergiou","year":"2018","journal-title":"Hypertension"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaa209\/36093988\/hpaa209.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajh\/article-pdf\/34\/4\/318\/37197914\/hpaa209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajh\/article-pdf\/34\/4\/318\/37197914\/hpaa209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T03:55:45Z","timestamp":1618977345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/34\/4\/318\/6040792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,17]]},"published-print":{"date-parts":[[2021,4,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaa209","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,12,17]]}}}